The administration has also suggested that it may impose significant tariffs on pharmaceuticals if “most-favored-nation” agreements are not reached with drug manufacturers. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements, the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.
